Working… Menu

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00055419
Recruitment Status : Completed
First Posted : March 4, 2003
Last Update Posted : April 9, 2010
Bristol-Myers Squibb
Information provided by:
Eli Lilly and Company

Brief Summary:
The purpose of this clinical research study is to learn about the safety of cetuximab in patients with stage IV colorectal cancer, and who may benefit from cetuximab.

Condition or disease Intervention/treatment Phase
Colorectal Neoplasms Biological: Cetuximab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 744 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
Study Start Date : February 2003
Actual Primary Completion Date : July 2004
Actual Study Completion Date : August 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Cetuximab

Arm Intervention/treatment
Experimental: 400 mg/m2 Biological: Cetuximab
400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
Other Name: Erbitux

Primary Outcome Measures :
  1. The objective of this study will be to monitor the safety of administering cetuximab,via an access program, to subjects with metastatic colorectal carcinoma who have exhausted all standard therapies or treatment options. [ Time Frame: Every 4 weeks untill disease progression ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have signed an approved informed consent prior to any study procedures.
  • Subjects with histologically or pathologically confirmed metastatic colorectal cancer, which is EGFR-positive by IHC (may be based on archival samples)
  • Subjects with ECOG performance status 0, 1 or 2.
  • Subjects who have failed, either due to lack of efficacy or due to intolerance, all available chemotherapy for the treatment of metastatic colorectal cancer.
  • Subjects who have failed to meet eligibility criteria for any other existing cetuximab trial.
  • Subjects must have received at least two chemotherapy regimens for metastatic disease OR adjuvant therapy plus one chemotherapy regimen for metastatic disease, provided the subject progressed within 6 months of completing their adjuvant therapy.
  • Prior chemotherapy must have included all of the follow drugs: irinotecan, oxaliplatin, and a fluoropyrimidine.
  • Subjects adequately recovered from any recent surgery, radiation therapy or chemotherapy.
  • Subjects accessible for treatment and follow-up. Subjects enrolled in this trial must be treated at the participating center.
  • Subjects greater or equal to 18 years of age.
  • Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks afterwards.

Exclusion Criteria:

  • Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study.
  • Women who are pregnant or breastfeeding.
  • Women with a positive pregnancy test on enrollment or prior to study drug administration.
  • Sexually active, fertile men not using adequate birth control.
  • Subjects with dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
  • Subjects with a serious uncontrolled medical disorder that would impair the ability of the patient to receive protocol therapy.
  • Subjects with a history of uncontrolled angina, arrhythmias, congestive heart failure, or myocardial infarction within the previous 6 months.
  • Subjects with any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. Subjects with a previous malignancy but without evidence of disease for > 5 years will be allowed to enter the trial.
  • Subjects with any history of severe hypersensitivity reactions and/or anaphylaxis resulting from the administration of protein based therapeutic agents.
  • Subjects with inadequate hematologic function defined by an absolute neutrophil count (ANC) <1,250/mm3, a platelet count <75,000/mm3, and a hemoglobin level <8 g/dL.
  • Subjects with inadequate hepatic function, defined by a total bilirubin level ³3 times the upper limit of normal (ULN) and an aspartate transaminase (AST) and alanine transaminase (ALT) levels >5 x ULN.
  • Subjects with inadequate renal function defined by a serum creatinine level >2.5 x ULN.
  • Prior cetuximab therapy, prior randomization on a study which includes cetuximab therapy in a treatment arm, or any other prior therapy that targets the EGFR pathway.
  • A history of prior therapy with a chimerized or murine monoclonal antibody.
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
  • A history of cetuximab or therapy that targeted the EGFR receptor.
  • A history of prior anti-cancer murine monoclonal antibody therapy.
  • Additional concurrent chemotherapy or other investigational anticancer agents may not be administered to subjects on this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00055419

  Show 29 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Bristol-Myers Squibb
Layout table for investigator information
Study Chair: E-mail: ClinicalTrials@ Eli Lilly and Company

Layout table for additonal information
Responsible Party: Chief Medical Officer, ImClone LLC Identifier: NCT00055419     History of Changes
Other Study ID Numbers: CA225-041
First Posted: March 4, 2003    Key Record Dates
Last Update Posted: April 9, 2010
Last Verified: April 2010
Keywords provided by Eli Lilly and Company:
Stage IV colorectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents